source
- Servier’s $1.55 B Edgewise muscular dystrophy trial fails to meet primary and secondary endpointsServier invested roughly $1.55 billion in Edgewise Therapeutics' muscular dystrophy program and, five months after the deal, announced that the pivotal phase 2 trial in Becker muscular dystrophy di…
- CVS Health to split into two publicly traded companies, separating pharmacy and insurance unitsCVS Health announced a plan to divide the company into two separate publicly listed entities. One entity will keep the CVS Health name and encompass the pharmacy retail and pharmacy benefit manage…